BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefit VCAR33 ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with ...
Using the 2 Stage Free Cash Flow to Equity, Vor Biopharma fair value estimate is US$0.31 With US$0.32 share price, Vor Biopharma appears to be trading close to its estimated fair value Analyst price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback